The Slow Safe Path
The bottom line: The newest predictions say the easiest drugs to get approved soon are the ones that are simplest to test fairly — and that MDMA, the one many veterans are waiting for, will likely need more proof first. If you or someone you love is hoping for legal psychedelic treatment, the honest message is this: it is coming, but it will arrive carefully, with strict rules, and probably slower than the headlines suggest.
What is happening right now is a quiet sorting. Our prediction engine ran 166 separate signals today, and the strongest agreements were not about a sudden breakthrough — they were about patience. Several predictions, each around 70 to 74 percent confidence, point the same way. The first: any near-term approval from the FDA — the U.S. agency that decides if a medicine is safe to sell — is more likely to favor ketamine-type drugs than MDMA or psilocybin. The reason is plain. Ketamine is easier to test honestly, while MDMA's trials had a problem: people could often tell whether they got the real drug or a fake one, which makes the results harder to trust. Another strong prediction says MDMA for PTSD — a heavy mental wound carried by many veterans — will likely need a fresh trial, pushing any decision past 2027. Meanwhile the market moved: two of the bigger psychedelic companies, ATAI and Compass, jumped 12.5 percent and 6.6 percent in a single day.
Beneath these numbers runs one steady thread: trust is being built before access is granted. The people in charge — lawmakers, drug regulators, FDA reviewers — keep landing on the same instinct. They will not throw the doors open. Several predictions agree that any approval will come wrapped in tight controls, meaning the drug could only be used under close supervision, like in a clinic, never bought freely. The same group agrees there will be no broad new law making psilocybin legal nationwide this Congress — only narrow rules for veterans and research. This is not a wall. It is a careful first step. The deepest current here is that the field is choosing the slow, sturdy path over the fast, fragile one — and that the sharp stock jumps may be running ahead of what has actually been proven.
For the real people inside this story, the feeling today is a mix of hope and ache. A veteran who has tried everything and finally heard that MDMA might help is now told to wait again — maybe two more years. That is hard. A family watching a parent slip under depression that no pill has touched wants the door open now. The truth is gentler than it sounds: a slower, safer path is the one most likely to actually reach them and stay reachable. A treatment that arrives carefully and earns trust will not be yanked away by the first scandal. The thing worth waiting for is the thing built to last.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
The medicine is older than the fear. The healing is older than the wound.
74%
Ketamine drugs will get US approval before MDMA or psilocybin
The FDA (the US drug regulator) is more likely to approve new ketamine-based medicines than MDMA or magic mushroom treatments in the near future. The problem with MDMA and psilocybin studies is that participants usually know whether they got the real drug or a placebo — which makes the results harder to trust. Ketamine studies don't have that problem as badly, so they're easier for regulators to evaluate.
→ Ketamine is winning the race to FDA approval because its clinical trials are easier to run cleanly — MDMA and psilocybin face a hard unsolved problem proving their studies are unbiased.
Resolves: 2027-06-30 · USA
RESEARCH
the precise call ▾
Any near-term FDA psychedelic action will favor ketamine-class agents with established blinding over MDMA/psilocybin.. Oral prolonged-release ketamine RCTs offer the methodological rigor I require; MDMA's unblinding remains unresolved. I protect patients, not narratives.
72%
Magic mushrooms will stay federally illegal for at least two more years
The US Congress is very unlikely to remove psilocybin (the active ingredient in magic mushrooms) from the federal list of banned substances during its current session. The only realistic small wins are narrow bills that let military veterans access treatment or expand research — not broad legalization or rescheduling for the general public.
→ Psilocybin stays federally illegal this Congress — the only movement will be small carve-outs for veterans or researchers, not anything that changes the rules for most people.
Resolves: 2026-12-22 · USA
LEGISLATION
the precise call ▾
No federal psilocybin rescheduling this Congress; only narrow veteran/research provisions advance.. Consensus of 4 agents: legislator, dea_officer, fda_reviewer. 1 dissenting.
72%
Congress won't legalize magic mushrooms — small veteran bills are the best case
There simply aren't enough votes in Congress right now to move psilocybin off the federal banned substances list. The one area where politicians across parties can agree is using it carefully for military veterans with conditions like PTSD (post-traumatic stress disorder). That narrow focus is what's actually achievable.
→ Full federal psilocybin reform has no path through the current Congress — veteran treatment provisions are the only bipartisan opening.
Resolves: 2027-01-03 · USA
LEGISLATION
the precise call ▾
No federal psilocybin rescheduling passes this Congress; only veteran/research carve-outs advance.. I can't get ahead of my district. Broad rescheduling has no votes. Narrow veteran provisions are the bipartisan sweet spot I can actually deliver.
72%
Any approved psychedelic drug will come with very strict safety controls
If a psychedelic drug does get FDA approval, it won't come with easy or open access. It will almost certainly require a special safety program — called a REMS (Risk Evaluation and Mitigation Strategy) — that limits who can prescribe it, where it can be given, and who can receive it. The DEA (the US agency that controls dangerous drugs) will also keep tight oversight. A patient death linked to an unsupervised session has made regulators more cautious, not less.
→ Approval doesn't mean accessibility — any psychedelic that gets through the FDA will be locked behind strict safety controls that limit who can give it and who can get it.
Resolves: 2028-06-25 · USA
REGULATION
the precise call ▾
Any psychedelic approval carries restrictive Schedule II-style REMS and DEA controls.. I won't sign off on loosened access. The Adelaide death shows what happens unsupervised. Tight controls are the only acceptable path to approval.
70%
Approved psychedelics will face tight government controls, not open access
Multiple regulators and officials agree: if any psychedelic gets approved as a medicine, it will come wrapped in strict rules. These include a REMS (a formal safety program that restricts who can prescribe and dispense a drug) and continued DEA (the US drug enforcement agency) oversight. This isn't about blocking treatment — it's about preventing misuse and harm outside supervised settings.
→ There is strong multi-agency agreement that psychedelic approval will mean controlled medical access — not anything resembling broad or easy availability.
Resolves: 2026-09-23 · USA
REGULATION
the precise call ▾
Any psychedelic approval carries restrictive REMS/DEA controls, not loosened access.. Consensus of 3 agents: dea_officer, fda_reviewer, legislator. 1 dissenting.